{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:31:52Z","timestamp":1792801912584,"version":"4.5.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":43,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100015311","name":"Novartis Institutes for BioMedical Research","doi-asserted-by":"publisher","award":["Novartis Institutes for BioMedical Research"],"award-info":[{"award-number":["Novartis Institutes for BioMedical Research"]}],"id":[{"id":"10.13039\/100015311","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI radiopharm. chem."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      PSMA-targeted radioligand therapy is a promising approach for the treatment of advanced prostate cancer; however, the clinical efficacy of [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-PSMA-617 (Pluvicto\n                      <jats:sup>\u00ae<\/jats:sup>\n                      ) is limited by the relatively low cytotoxic potency of the \u03b2-emitting radionuclide\n                      <jats:sup>177<\/jats:sup>\n                      Lu (t\n                      <jats:sub>1\/2<\/jats:sub>\n                      : 6.65 d). This has driven high interest in \u03b1-emitting radionuclides, such as\n                      <jats:sup>212<\/jats:sup>\n                      Pb (t\n                      <jats:sub>1\/2<\/jats:sub>\n                      : 10.64\u00a0h) and\n                      <jats:sup>225<\/jats:sup>\n                      Ac (t\n                      <jats:sub>1\/2<\/jats:sub>\n                      : 9.92 d), which deliver high Linear Energy Transfer (LET) and cause more potent tumor cell killing. In this work, we assessed the radiolabeling and in vitro characteristics of\n                      <jats:sup>212<\/jats:sup>\n                      Pb- and\n                      <jats:sup>225<\/jats:sup>\n                      Ac-labeled PSMA-617 compared with [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]LuPSMA-617, using two different PSMA-positive prostate cancer cell lines, LNCaP-AR and DU145-PSMA, along with paired negative controls.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The radioligands were synthesized with an isolated radiochemical yield of &gt;\u200995% for [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-PSMA-617 and about 45% for [\n                      <jats:sup>212<\/jats:sup>\n                      Pb]Pb-PSMA-617 and [\n                      <jats:sup>225<\/jats:sup>\n                      Ac]Ac-PSMA-617. The molar activity after Sep-Pak purification was about 37.0 MBq\/nmol for [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-PSMA-617, 4.4\u201311.1 MBq\/nmol for [\n                      <jats:sup>212<\/jats:sup>\n                      Pb]Pb-PSMA-617, and 0.22\u20130.55 MBq\/nmol for [\n                      <jats:sup>225<\/jats:sup>\n                      Ac]Ac-PSMA-617. In vitro stability studies in PBS, human serum, and whole blood revealed\u2009\u2265\u200990% stability for [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-PSMA-617 (up to 5 days) and [\n                      <jats:sup>212<\/jats:sup>\n                      Pb]Pb-PSMA-617 (24\u00a0h), whereas [\n                      <jats:sup>225<\/jats:sup>\n                      Ac]Ac-PSMA-617 exhibited\u2009~\u200972% stability in PBS, &gt;\u200994% in serum, and &gt;\u200986% in whole blood for 5 days. The uptake of [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-PSMA-617 in LNCaP-AR cells was 7.5\u2009\u00b1\u20090.6%, with about 33% of the cell-bound activity internalized at 4\u00a0h. The uptake and internalization were significantly higher in the PSMA-overexpressing cell line DU145-PSMA (31.1\u2009\u00b1\u20090.6%, 65% internalized). Compared to [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-PSMA-617, [\n                      <jats:sup>212<\/jats:sup>\n                      Pb]Pb-PSMA-617 showed about 2-fold higher uptake and increased internalization in LNCaP-AR cells at 4\u00a0h (14.2\u2009\u00b1\u20090.0%, 47.1% internalized), but a similar uptake in DU145-PSMA cells (29.3\u2009\u00b1\u20090.7%, 62% internalized). In contrast, [\n                      <jats:sup>225<\/jats:sup>\n                      Ac]Ac-PSMA-617 exhibited lower uptake in both cell lines, with 1.6\u2009\u00b1\u20090.2% in LNCaP-AR cells and 4.6\u2009\u00b1\u20090.2% in DU145-PSMA cells after 4\u00a0h incubation. For all 3 radioligands, the uptake could be fully blocked by co-incubation with unlabeled PSMA-617 (300 nM), confirming the specificity of binding to PSMA, and the uptake was minimal in the paired PSMA-negative cell lines CWRR1-EnzR and DU145. In saturation binding assays, the three radioligands exhibited comparable binding affinities (\n                      <jats:italic>K<\/jats:italic>\n                      <jats:sub>D<\/jats:sub>\n                      ) in LNCaP-AR and DU145-PSMA cell lines, with 5.9\u2009\u00b1\u20090.7 nM and 2.3\u2009\u00b1\u20090.3 nM for [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-PSMA-617, 5.7\u2009\u00b1\u20090.5 nM and 5.8\u2009\u00b1\u20090.9 nM for [\n                      <jats:sup>225<\/jats:sup>\n                      Ac]Ac-PSMA-617, and 2.7\u2009\u00b1\u20090.5 nM and 8.0\u2009\u00b1\u20091.1 nM for [\n                      <jats:sup>212<\/jats:sup>\n                      Pb]Pb-PSMA-617, respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      [\n                      <jats:sup>212<\/jats:sup>\n                      Pb]Pb-PSMA-617 showed similar or better uptake in PSMA-positive cell lines compared to [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-PSMA-617. While [\n                      <jats:sup>225<\/jats:sup>\n                      Ac]Ac-PSMA-617 also showed selective and specific uptake in the two PSMA-positive cell lines, the uptake levels were substantially lower, likely due to the low molar activities achievable for [\n                      <jats:sup>225<\/jats:sup>\n                      Ac]Ac-PSMA-617 compared to [\n                      <jats:sup>212<\/jats:sup>\n                      Pb]Pb-PSMA-617 or [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-PSMA-617.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s41181-026-00456-w","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T12:05:31Z","timestamp":1779278731000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Radiochemistry and comparative in vitro assessment of PSMA-617 labeled with lead-212 (212Pb), actinium-225 (225Ac), and lutetium-177 (177Lu)"],"prefix":"10.1186","volume":"11","author":[{"given":"Abhijit","family":"Bera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham","family":"Ragland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia G.","family":"Madel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmine","family":"B\u2019Lanton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atchimnaidu","family":"Siriki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chin-Tu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell Z.","family":"Szmulewitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1183-2286","authenticated-orcid":false,"given":"Satish K.","family":"Chitneni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"issue":"6","key":"456_CR2","doi-asserted-by":"publisher","first-page":"914","DOI":"10.2967\/jnumed.114.147413","volume":"56","author":"M Benesova","year":"2015","unstructured":"Benesova M, Schafer M, Bauder-Wust U, Afshar-Oromieh A, Kratochwil C, Mier W, Eder M. Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer. J Nucl Med. 2015;56(6):914\u201320.","journal-title":"J Nucl Med"},{"issue":"5","key":"456_CR1","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1021\/acs.jmedchem.5b01210","volume":"59","author":"M Benesova","year":"2016","unstructured":"Benesova M, Bauder-Wust U, Schafer M, Klika KD, Mier W, Haberkorn U, Eder M. Linker Modification Strategies To Control the Prostate-Specific Membrane Antigen (PSMA)-Targeting and Pharmacokinetic Properties of DOTA-Conjugated PSMA Inhibitors. J Med Chem. 2016;59(5):1761\u201375.","journal-title":"J Med Chem"},{"key":"456_CR3","doi-asserted-by":"crossref","unstructured":"Busslinger SD, Tschan VJ, Richard OK, Talip Z, Schibli R, M\u00fcller C. (2022). [225Ac]Ac-SibuDAB for Targeted Alpha Therapy of Prostate Cancer: Preclinical Evaluation and Comparison with [225Ac]Ac-PSMA-617. Cancers, 14(22).","DOI":"10.3390\/cancers14225651"},{"issue":"7","key":"456_CR4","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1021\/acsmedchemlett.7b00478","volume":"9","author":"SK Chitneni","year":"2018","unstructured":"Chitneni SK, Yan H, Zalutsky MR. Synthesis and Evaluation of a 18F-Labeled Triazinediamine Analogue for Imaging Mutant IDH1 Expression in Gliomas by PET. ACS Med Chem Lett. 2018;9(7):606\u201311.","journal-title":"ACS Med Chem Lett"},{"issue":"10276","key":"456_CR5","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","volume":"397","author":"MS Hofman","year":"2021","unstructured":"Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC, Trials PC, G. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021;397(10276):797\u2013804.","journal-title":"Lancet"},{"key":"456_CR6","doi-asserted-by":"crossref","unstructured":"Hooijman EL, Chalashkan Y, Ling SW, Kahyargil FF, Segbers M, Bruchertseifer F, de Blois E. (2021). Development of [225Ac]Ac-PSMA-I&T for Targeted Alpha Therapy According to GMP Guidelines for Treatment of mCRPC. Pharmaceutics, 13(5).","DOI":"10.3390\/pharmaceutics13050715"},{"issue":"3","key":"456_CR7","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.euo.2023.07.018","volume":"7","author":"M Kafka","year":"2024","unstructured":"Kafka M, Horninger A, di Santo G, Virgolini I, Neuwirt H, Unterrainer LM, Heidegger I. Real-world Outcomes and Predictive Biomarkers for (177)Lutetium Prostate-specific Membrane Antigen Ligand Treatment in Metastatic Castration-resistant Prostate Cancer: A European Association of Urology Young Academic Urologists Prostate Cancer Working Group Multi-institutional Observational Study. Eur Urol Oncol. 2024;7(3):421\u20139.","journal-title":"Eur Urol Oncol"},{"issue":"12","key":"456_CR8","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.2967\/jnumed.116.178673","volume":"57","author":"C Kratochwil","year":"2016","unstructured":"Kratochwil C, Bruchertseifer F, Giesel FL, Weis M, Verburg FA, Mottaghy F, Morgenstern A. 225Ac-PSMA-617 for PSMA-Targeted alpha-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer. J Nucl Med. 2016;57(12):1941\u20134.","journal-title":"J Nucl Med"},{"issue":"6","key":"456_CR9","first-page":"485","volume":"75","author":"TB Kratzer","year":"2025","unstructured":"Kratzer TB, Mazzitelli N, Star J, Dahut WL, Jemal A, Siegel RL. Prostate cancer statistics, 2025. CA Cancer J Clin. 2025;75(6):485\u201397.","journal-title":"CA Cancer J Clin"},{"key":"456_CR10","doi-asserted-by":"crossref","unstructured":"Peng CL, Chen CT, Tang IC. (2025). Exploring the Therapeutic Potential of 177Lu-PSMA-617 in a Mouse Model of Prostate Cancer Bone Metastases. Int J Mol Sci, 26(13).","DOI":"10.3390\/ijms26135970"},{"issue":"12","key":"456_CR11","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, Investigators V. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2021;385(12):1091\u2013103.","journal-title":"N Engl J Med"},{"issue":"3","key":"456_CR12","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/jlcr.3825","volume":"63","author":"VY Stenberg","year":"2020","unstructured":"Stenberg VY, Juzeniene A, Chen Q, Yang X, Bruland \u00d8S, Larsen RH. Preparation of the alpha-emitting prostate-specific membrane antigen targeted radioligand [212Pb]Pb-NG001 for prostate cancer. J Label Compd Radiopharm. 2020;63(3):129\u201343.","journal-title":"J Label Compd Radiopharm"},{"issue":"6","key":"456_CR13","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.7150\/thno.42228","volume":"10","author":"AD Stuparu","year":"2020","unstructured":"Stuparu AD, Meyer CAL, Evans-Axelsson SL, Luckerath K, Wei LH, Kim W, Slavik R. Targeted alpha therapy in a systemic mouse model of prostate cancer - a feasibility study. Theranostics. 2020;10(6):2612\u201320.","journal-title":"Theranostics"},{"issue":"3","key":"456_CR14","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"10","key":"456_CR15","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.2967\/jnumed.121.263371","volume":"63","author":"A Wurzer","year":"2022","unstructured":"Wurzer A, Kunert JP, Fischer S, Felber V, Beck R, de Rose F, Wester HJ. Synthesis and Preclinical Evaluation of 177Lu-Labeled Radiohybrid PSMA Ligands for Endoradiotherapy of Prostate Cancer. J Nucl Med. 2022;63(10):1489\u201395.","journal-title":"J Nucl Med"},{"issue":"20","key":"456_CR16","doi-asserted-by":"publisher","first-page":"9364","DOI":"10.7150\/thno.48107","volume":"10","author":"MP Yadav","year":"2020","unstructured":"Yadav MP, Ballal S, Sahoo RK, Tripathi M, Seth A, Bal C. Efficacy and safety of 225Ac-PSMA-617 targeted alpha therapy in metastatic castration-resistant Prostate Cancer patients. Theranostics. 2020;10(20):9364\u201377.","journal-title":"Theranostics"},{"issue":"3","key":"456_CR17","doi-asserted-by":"publisher","first-page":"228","DOI":"10.3934\/medsci.2015.3.228","volume":"2","author":"K Yong","year":"2015","unstructured":"Yong K, Brechbiel M. Application of 212Pb for Targeted alpha-particle Therapy (TAT): Pre-clinical and Mechanistic Understanding through to Clinical Translation. AIMS Med Sci. 2015;2(3):228\u201345.","journal-title":"AIMS Med Sci"},{"issue":"2","key":"456_CR18","doi-asserted-by":"publisher","first-page":"176","DOI":"10.2967\/jnumed.123.266774","volume":"65","author":"R Zimmermann","year":"2024","unstructured":"Zimmermann R. Is 212Pb Really Happening? The Post-177Lu\/225Ac Blockbuster? J Nucl Med. 2024;65(2):176\u20137.","journal-title":"J Nucl Med"}],"container-title":["EJNMMI Radiopharmacy and Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41181-026-00456-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41181-026-00456-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41181-026-00456-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T11:00:52Z","timestamp":1782990052000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s41181-026-00456-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,20]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["456"],"URL":"https:\/\/doi.org\/10.1186\/s41181-026-00456-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-9419820\/v1","asserted-by":"object"}]},"ISSN":["2365-421X"],"issn-type":[{"value":"2365-421X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,20]]},"assertion":[{"value":"17 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no financial or proprietary interests in any material discussed in this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"42"}}